Literature DB >> 8324796

Protection from ischaemic-reperfusion injury with adenosine pretreatment is reversed by inhibition of ATP sensitive potassium channels.

C F Toombs1, D S McGee, W E Johnston, J Vinten-Johansen.   

Abstract

OBJECTIVE: The aim was to test the hypothesis that the cardioprotective effects against ischaemic-reperfusion injury of pretreatment with adenosine are mediated in part by activation of ATP sensitive potassium channels (K+ATP channels).
METHODS: 42 anaesthetised New Zealand White rabbits underwent 30 min coronary occlusion, followed by 2 h reperfusion. Half the animals received a 5 min infusion of 140 micrograms.kg-1.min-1 of adenosine as pretreatment. The remainder of the animals received a 5 min infusion of saline alone as pretreatment. Animals pretreated with adenosine received either a low dose of the K+ATP channel blocker glibenclamide (0.3 mg.kg-1), high dose glibenclamide (3.0 mg.kg-1), or vehicle immediately prior to ischaemia to test whether glibenclamide can reverse the protective effects of adenosine, thus allowing the adenosine effect but antagonising K(+)ATP channel activation during ischaemia. Animals which received saline pretreatment also received low dose glibenclamide, high dose glibenclamide, or vehicle (controls) to evaluate the effect of glibenclamide alone. Infarct size was determined with tetrazolium and Unisperse Blue stains, and transmural blood flow was measured using radioactive microspheres.
RESULTS: Although there were no differences in collateral myocardial blood flow during ischaemia or in risk area among the groups, infarct size was reduced by adenosine pretreatment to 8 (SEM 3)% v 36(4)% in controls (p < 0.05). K(+)ATP channel blockade with low dose glibenclamide in saline pretreated animals did not by itself extend the degree of necrosis [33(4)%], whereas low dose glibenclamide prevented the protective effects of adenosine pretreatment [38(3)%]. High dose glibenclamide reversed adenosine protection as well [54(3)%], but at a dose which increased infarct size in saline pretreated animals [52(3)%].
CONCLUSIONS: While adenosine pretreatment protects against necrosis in the rabbit, (1) the expression of this protection depends at least in part upon the actions of K(+)ATP channels during ischaemia, and (2) glibenclamide at higher doses increases infarct size, suggesting either that the K(+)ATP channel is endogenously protective during ischaemia, or that the higher dose has other infarct extending effects.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8324796     DOI: 10.1093/cvr/27.4.623

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  6 in total

Review 1.  ATP-sensitive potassium channels and myocardial preconditioning.

Authors:  G J Gross
Journal:  Basic Res Cardiol       Date:  1995 Mar-Apr       Impact factor: 17.165

2.  Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia.

Authors:  G P Matherne; J Linden; A M Byford; N S Gauthier; J P Headrick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

3.  Remote ischemic preconditioning fails to reduce infarct size in the Zucker fatty rat model of type-2 diabetes: role of defective humoral communication.

Authors:  Joseph Wider; Vishnu V R Undyala; Peter Whittaker; James Woods; Xuequn Chen; Karin Przyklenk
Journal:  Basic Res Cardiol       Date:  2018-03-09       Impact factor: 17.165

4.  Ischemic and pharmacological preconditioning induces further delayed protection in transgenic mouse cardiac myocytes over-expressing adenosine A1 receptors (A1AR): role of A1AR, iNOS and K(ATP) channels.

Authors:  Mohammed A Nayeem; G Paul Matherne; S Jamal Mustafa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-25       Impact factor: 3.000

5.  Inhibition of glycolysis and enhanced mechanical function of working rat hearts as a result of adenosine A1 receptor stimulation during reperfusion following ischaemia.

Authors:  B A Finegan; G D Lopaschuk; M Gandhi; A S Clanachan
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

Review 6.  Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?

Authors:  G Leibowitz; E Cerasi
Journal:  Diabetologia       Date:  1996-05       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.